Stoke Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 110
- Market Cap
- $730.2M
- Introduction
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Stoke Therapeutics, Inc. SEC 10-Q Report
Stoke Therapeutics released its Q3 2023 Form 10-Q, reporting $4.9M in revenue (+$1.6M QoQ) and a net loss of $26.4M. The company is advancing clinical programs for zorevunersen (Dravet syndrome) and STK-002 (ADOA), with regulatory updates planned for H2 2024. Stoke faces challenges including clinical trial uncertainty and regulatory approval risks.
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics reported positive data from STK-001 studies in Dravet syndrome patients, showing significant seizure reduction and cognitive improvements. The FDA approved a dosing regimen, and the company plans regulatory discussions for a registrational study. STOK stock surged following the update.
© Copyright 2025. All Rights Reserved by MedPath